MedPath

To study the effects of two probiotic strain in preterm infants.

Phase 3
Conditions
Health Condition 1: null- Feeding Intolerance and NEC and late onset sepsis
Registration Number
CTRI/2017/06/008907
Lead Sponsor
Dr Sandeep Kadam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Gestation less than 33 weeks

2. birth weight less than 1500 gms

3. ready to commence on enteral feed or on enteral feed for less than 12 hours

Exclusion Criteria

1. major congenital malformation

2. chromosomal aberration

3. no consent

4. on enteral feeds for more than 12 hours

5. contraindication for enteral feeding

6. life threatening illness

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
(1) Safety: Assessed by monitoring for blood culture positive sepsis by the administered probiotic strains (2) Tolerance: The tolerance to study supplement will be assessed by monitoring for adverse effects such as abdominal distension, vomiting, and diarrhea leading to cessation of the supplementation (3) Effect on fecal microbiota: Lactobacillus counts will be determined by qPCR method.Timepoint: 4 weeks
Secondary Outcome Measures
NameTimeMethod
(1) Incidence of NEC â?¥Stage II (2) All-cause mortality (3) Composite of NEC â?¥Stage II/all-cause mortality (3) Blood culture positive late onset sepsis (LOS) beyond 72 hours of life (4) Time to reach full enteral feeds (TFF: 150 ml/kg/day).Laboratory based: (5) Fecal bifidobacteria countsto be determined qPCR (6) Fecal metagenomics.Timepoint: 4 weeks
© Copyright 2025. All Rights Reserved by MedPath